Three-day therapy of vulvovaginal candidiasis with econazole: a multicentric study comprising 996 cases.
Within the scope of three open multicentric studies, effect and tolerability of 150 mg. econazole vaginal suppositories were tested in a total of 996 women, 13 to 74 years old (mean age, 29 years). Vaginal candidiasis had been mycologically demonstrated in every patient prior to therapy, and the total cure rate of 93.4 per cent in Studies I and II (880 patients) was also mycologically confirmed. The tolerability was tested by checking of 30 laboratory variables before and after the treatment of 116 patients (Study III); no therapy-related adverse changes were recorded. Connections between therapeutic results, age distribution, initial hormonal situation, and conception of the therapy are pointed out.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D004334:Drug Administration Schedule; D004464:Econazole / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D013488:Suppositories; D014621:Vagina
D007093:Imidazoles; D013488:Suppositories; D004464:Econazole